Gyula

• A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active … Ended recruitment
  2024-516213-20-00 5 2025-03-25 Psoriatic arthritis
• A clinical study investigating OM-85 efficacy and safety in children suffering from Recurrent Wheezing Ended recruitment
  2024-511083-90-00 4 2024-10-03 Recurrent wheezing
• A study to find how well Dazodalibep works and how safe it is in participants with Sjögren’s Syndrome Ended recruitment
  2023-503923-24-00 5 2024-07-22 Sjögren’s Syndrome With Moderate-toSevere Symptom State
• A study to evaluate the safety and the activity of S095029 as a part of combination therapy in advanced gastroesophageal junction/gastric ca … Ended recruitment
  2023-507995-33-00 9 2024-05-23 MSI-H/dMMR Gastric cancer
• A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis (REZOLV … Ended recruitment
  2023-507456-69-00 4 2024-04-25 Atopic Dermatitis
• A study to test the effect of BI 456906 on cardiovascular safety in people with overweight or obesity Ended recruitment
  2022-502442-27-00 5 2024-01-08 Obesity
• Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic … Ended recruitment
  2023-503655-10-00 5 2023-11-20 Systemic Lupus Erythematosus (SLE).
• A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjögren’ … Ended recruitment
  2022-502966-26-01 5 2023-10-27 Sjögren’s syndrome
• Phase 2 Placebo-controlled Study to Assess the Safety, Efficacy, and PK of ESK-001 in SLE Ended recruitment
  2022-502105-15-00 4 2023-10-20 Systemic lupus erythematosus
• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Ended recruitment
  2022-502779-40-00 5 2023-09-04 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended recruitment
  2022-501024-20-00 5 2023-07-25 ER+/HER2- Early Breast Cancer
• HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation. Ended recruitment
  2022-501939-16-00 5 2023-05-09 Heart failure (HF) with mildly reduced ejection fraction (HFmrEF) or H
• Phase 3 study to evaluate two regimens of ianalumab on top of standardof- care therapy in patients with systemic lupus erythematosus (SIRIUS … Ended recruitment
  2023-508498-97-00 5 2023-02-03 Systemic Lupus Erythematosus
• OM 85 in Paediatric Recurrent Respiratory Tract Infections with Wheezing Lower Respiratory Illness Ended recruitment
  2024-511581-37-00 6 2022-11-25 Respiratory Tract Infections with Wheezing Lower Respiratory Illness
• Three-arm study of the clinical efficacy, safety and tolerability of ianalumab (VAY736) in patients with active Sjögren’s syndrome Ended recruitment
  2024-511068-10-00 5 2022-08-04 Sjögren’s Syndrome
• A clinical trial to compare the effectiveness and safety of giredestrant with a subcutaneous combination of pertuzumab and trastuzumab versu … Ended recruitment
  2022-500014-26-00 5 2022-06-24 Locally-Advanced unresectable or Metastatic breast cancer (MBC)
• A Study to Evaluate the Continuous Safety and Efficacy of Litifilimab (BIIB059) in Adults With Active Systemic Lupus Erythematosus (EMERALD) Ended recruitment
  2023-505635-13-00 5 2022-06-10 Systemic lupus erythematosus
• Efficacy and safety of Frexalimab (SAR441344) in the treatment of Systemic Lupus Erythematosus Ended recruitment
  2023-508654-26-00 4 2022-03-15 Systemic lupus erythematosus
• A Study to Evaluate the Efficacy and Safety of BIIB059 in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background N … Ended recruitment
  2023-505696-74-00 5 2022-02-10 systemic lupus erythematosus
• An International, Randomized, Double-Blind, Phase III Study of Fuzuloparib Combined with Abiraterone Acetate and Prednisone (AA-P) versus Pl … Ended recruitment
  2023-509396-16-00 5 2021-11-08 Metastatic Castration-Resistant Prostate Cancer
• Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active Psoriatic Arthritis (PsA) who are Naïve to Biologic … Ended recruitment
  2023-506257-37-00 5 2021-10-29 Active Psoriatic Arthritis
• Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus Ended recruitment
  2024-513031-24-00 10 2021-10-22 Moderate-to-severe Systemic Lupus Erythematosus (SLE)
• Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active Psoriatic Arthritis (PsA) who are Naïve to Biologic … Ended recruitment
  2023-506256-25-00 5 2021-10-20 Active Psoriatic Arthritis
• A study to learn if dapirolizumab pegol is safe and works long-term in people with systemic lupus erythematosus Ended recruitment
  2023-506368-14-00 5 2021-09-07 Systemic lupus erythematosus (SLE)

Showing 49–72 of 106 trials